<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Non-immune (Coombs-negative) hemolytic anemias in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Non-immune (Coombs-negative) hemolytic anemias in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Non-immune (Coombs-negative) hemolytic anemias in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert A Brodsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert T Means, Jr, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the most useful ways to classify anemia is whether red cell production is decreased or destruction is increased. Hemolysis is the primary form of red cell destruction.
        </p>
        <p>
         Hemolytic anemias can be classified as immune (antibody mediated) or non-immune. Immune hemolysis generally can be treated by immunomodulatory drugs, whereas non-immune hemolysis does not respond to immune suppression.
        </p>
        <p>
         This topic discusses non-immune hemolytic anemias in adults. Separate topic reviews discuss:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic approach to anemia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis of hemolytic anemia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune hemolysis
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">
          "Paroxysmal cold hemoglobinuria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H255953248">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia definitions and red blood cell (RBC) indices are listed separately. (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults", section on 'Basic principles'
         </a>
         .)
        </p>
        <p>
         All RBCs are eventually destroyed, typically after approximately 120 days. Each day, they undergo repeated cycles of metabolic and physical stress as they circulate through the capillary microvasculature and splenic sinusoids. Accumulated damage to the RBC membrane leads to culling by splenic macrophages that phagocytose pieces of the RBC membrane and ultimately the entire RBC.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolysis versus hemolytic anemia
         </strong>
         – Hemolysis refers to premature RBC destruction. An RBC lifespan of &lt;100 days qualifies, although RBC survival is not measured outside of research studies. (See
         <a class="medical medical_review" href="/z/d/html/7082.html" rel="external">
          "Red blood cell survival: Normal values and measurement"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Regardless of the cause of hemolysis, typical findings include increased reticulocyte count (compensatory), high lactate dehydrogenase (LDH) and indirect bilirubin (released from lysed RBCs), and low or undetectable haptoglobin (hemoglobin scavenger protein). The table summarizes these findings  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 1
         </a>
         ). When hemolysis is severe and bone marrow function is normal, the reticulocyte count can reach 20 to 30 percent of RBCs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hemolytic anemia occurs when hemolysis is too great to be compensated by RBC production in the bone marrow, or when bone marrow compensation is impaired for another reason.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune versus non-immune hemolysis
         </strong>
         – The Coombs test (also called direct antiglobulin test [DAT]) is generally used to determine whether hemolysis is immune (antibody-mediated) or non-immune. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Cause not obvious - start with Coombs test'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immune
         </strong>
         – Immune hemolysis generally refers to antibody-mediated RBC destruction. The antibodies can be autoantibodies (as in autoimmune hemolytic anemia [AIHA]) or alloantibodies, as in hemolytic transfusion reactions or hemolytic disease of the fetus and newborn (HDFN). In immune hemolysis, the Coombs test is typically positive.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Antibodies can destroy RBCs by fixing complement and causing the cells to be lysed in the circulation (intravascular hemolysis) or by opsonizing the cells and making them susceptible to phagocytosis by macrophages of the reticuloendothelial system in the spleen and liver (extravascular hemolysis).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Destruction of RBCs in the spleen due to hypersplenism, which involves non-antibody-mediated phagocytosis, is generally considered to be non-immune.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-immune
         </strong>
         – Non-immune (Coombs-negative) hemolysis includes all non-antibody-mediated hemolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Non-immune hemolysis can result from intrinsic properties of the RBC (abnormalities of the membrane, hemoglobin, or metabolic enzymes) or extrinsic factors including infectious organisms, oxidant drugs, toxins, mechanical or chemical destruction, vascular changes, hypersplenism, or others.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravascular versus extravascular
         </strong>
         – Intravascular hemolysis occurs within the circulation. Extravascular hemolysis occurs in the reticuloendothelial system (macrophages of the spleen and liver). Severe hemolysis can "spill over" and occur in both sites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intravascular hemolysis releases free heme, which can cause acute kidney injury from heme pigment. Aggressive hydration and monitoring may be indicated. (See
         <a class="local">
          'General management principles'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H288717919">
         <span class="h1">
          CAUSES
         </span>
        </p>
        <p class="headingAnchor" id="H1847971627">
         <span class="h2">
          Heritable/genetic causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heritable anemias are generally caused by variants in genes that encode red blood cell (RBC) membrane/cytoskeletal proteins, hemoglobin, or metabolic enzymes  (
         <a class="graphic graphic_figure graphicRef117376" href="/z/d/graphic/117376.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Details of evaluation and management are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Membrane/cytoskeletal proteins
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7079.html" rel="external">
          "Hereditary spherocytosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemoglobin
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">
          "Diagnosis of sickle cell disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">
          "Diagnosis of thalassemia (adults and children)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7086.html" rel="external">
          "Unstable hemoglobin variants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enzymes
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7129.html" rel="external">
          "Pyruvate kinase deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7128.html" rel="external">
          "Rare RBC enzyme disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H795804360">
         <span class="h2">
          Infections (RBC parasites and intracellular bacteria)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain infectious organisms can lyse RBCs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malaria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Babesia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leishmania
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Clostridium perfringens
         </em>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bartonella
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protozoa
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Malaria
         </strong>
         – Plasmodial parasites attach to receptors on the RBC surface (for
         <em>
          Plasmodium vivax
         </em>
         , the Duffy antigen; for
         <em>
          Plasmodium falciparum
         </em>
         , sialic acid residues on glycophorin A of the MNS blood group). CD55 is also an essential host factor for
         <em>
          P. falciparum
         </em>
         invasion [
         <a href="#rid1">
          1
         </a>
         ]. They grow inside the RBC  (
         <a class="graphic graphic_picture graphicRef77517" href="/z/d/graphic/77517.html" rel="external">
          picture 1
         </a>
         ) using the RBC's metabolic machinery and ingesting hemoglobin [
         <a href="#rid2">
          2-4
         </a>
         ]. RBCs are lysed when the mature schizont lyses the RBC  (
         <a class="graphic graphic_picture graphicRef131195" href="/z/d/graphic/131195.html" rel="external">
          picture 2
         </a>
         ). Diagnosis is made via the blood smear. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5703.html" rel="external">
          "Pathogenesis of malaria", section on 'Life cycle'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7112.html" rel="external">
          "Anemia in malaria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Babesia
         </strong>
         –
         <em>
          Babesia microti
         </em>
         parasites  (
         <a class="graphic graphic_picture graphicRef110026" href="/z/d/graphic/110026.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef131054" href="/z/d/graphic/131054.html" rel="external">
          picture 4
         </a>
         ) are transmitted by deer ticks (
         <em>
          Ixodes scapularis
         </em>
         ), mostly in the Northeast and upper Midwest of the United States, especially in the summer. The tick may also transmit Lyme disease and ehrlichiosis [
         <a href="#rid5">
          5
         </a>
         ]. Babesiosis can occur in people who are immunocompetent, but the most severe disease is seen in people who are immunocompromised or asplenic [
         <a href="#rid6">
          6-10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5734.html" rel="external">
          "Babesiosis: Microbiology, epidemiology, and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Leishmania
         </strong>
         –
         <em>
          Leishmania donovani
         </em>
         parasitizes macrophages, not RBCs. The organism is transmitted by the bite of a sandfly, especially in South Asia (India, Bangladesh, and Nepal) and the Horn of Africa (Sudan, Ethiopia, Kenya, and Somalia). Some infections are asymptomatic; others can cause visceral leishmaniasis (also called "kala-azar," meaning "black fever"). Parasites cause anemia by multiple mechanisms including splenic sequestration, hemolysis, and bone marrow suppression [
         <a href="#rid11">
          11
         </a>
         ]. Hemolysis is thought to involve oxidative metabolic products [
         <a href="#rid12">
          12
         </a>
         ]. People who develop kala-azar may have deficiencies in enzymes that are protective against oxidative damage [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5732.html" rel="external">
          "Visceral leishmaniasis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bacteria
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           Clostridium perfringens
          </em>
         </strong>
         – Infection by
         <em>
          C. perfringens
         </em>
         (formerly called
         <em>
          C. Welchii)
         </em>
         can cause massive, life-threatening hemolysis. Clostridial sepsis is a
         <strong>
          medical emergency
         </strong>
         ; people with clostridial sepsis often die within hours of presentation. If there is even the slightest suspicion of clostridial sepsis, parenteral antibiotic therapy should be started immediately (see
         <a class="medical medical_review" href="/z/d/html/7672.html" rel="external">
          "Clostridial myonecrosis", section on 'Treatment'
         </a>
         ). The mechanism of hemolysis is thought to involve alpha toxin, a phospholipase C enzyme that destroys RBC membrane phospholipids and structural membrane proteins [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Infection can complicate surgery (gastrointestinal or genitourinary abscess), pregnancy, cancer, or diabetes [
         <a href="#rid15">
          15-18
         </a>
         ]. Any site of infection can cause sepsis and fatal hemolysis [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7672.html" rel="external">
          "Clostridial myonecrosis", section on 'Traumatic gas gangrene'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The laboratory may have difficulty performing chemical assays or pretransfusion testing (crossmatching) due to massive hemolysis; this may be confused with faulty sample collection [
         <a href="#rid16">
          16,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Within hours, the peripheral blood smear may show hemolyzed "ghost" red cells  (
         <a class="graphic graphic_picture graphicRef53404" href="/z/d/graphic/53404.html" rel="external">
          picture 5
         </a>
         ), spherocytosis, erythrophagocytosis, phagocytic cells containing bacilli, and toxic changes in white blood cells [
         <a href="#rid15">
          15,16,21-24
         </a>
         ]. Disseminated intravascular coagulation (DIC) and acute kidney injury (AKI) can occur [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bartonella
         </strong>
         –
         <em>
          Bartonella bacilliformis
         </em>
         is a gram-negative bacterium transmitted by the bite of a sandfly, mostly in the Andes Mountains of Peru, Colombia, and Ecuador, with sporadic cases in other South American countries. The organism can infect RBCs intracellularly, possibly mediated by the bacterial flagellum [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5516.html" rel="external">
          "South American bartonellosis: Oroya fever and verruga peruana"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H177319254">
         <span class="h2">
          Oxidant drugs and toxins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oxidant drugs that cause hemolysis include
         <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">
          primaquine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9761" href="/z/d/drug information/9761.html" rel="external">
          phenazopyridine
         </a>
         ; others are listed in the table  (
         <a class="graphic graphic_table graphicRef74254" href="/z/d/graphic/74254.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Hemolysis is exacerbated by glucose-6-phosphate dehydrogenase (G6PD) deficiency, but oxidant drugs can cause hemolysis even if G6PD levels are normal. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia", section on 'Oxidant injury'
         </a>
         .)
        </p>
        <p>
         Evaluation for G6PD deficiency and management are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p>
         Venoms from certain insect bites and stings can cause a DIC-like picture with a coagulopathy and hemolytic anemia; these include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Hemiscorpius lepturus
         </em>
         , a scorpion found in hot and humid regions of the Middle East. (See
         <a class="medical medical_review" href="/z/d/html/117074.html" rel="external">
          "Scorpion envenomation causing skin necrosis, hemolysis, DIC, and acute kidney injury (Middle East)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Snakebite (several species). (See
         <a class="medical medical_review" href="/z/d/html/6594.html" rel="external">
          "Snakebites worldwide: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93182.html" rel="external">
          "Snakebites worldwide: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Treatment is supportive with antivenom, hydration, and hemodynamic support. (See
         <a class="local">
          'General management principles'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2719532331">
         <span class="h2">
          Fragmentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasculature abnormalities can fragment RBCs, forming schistocytes (also called helmet cells or poikilocytes)  (
         <a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">
          picture 6
         </a>
         ). The RBCs can be triangular or crescent-shaped with pointed projections and lacking central pallor [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The gold standard for schistocyte determination is examination of a suitably prepared peripheral blood smear by an experienced observer. Automated cell counters can detect schistocytes, especially when they represent ≥1 percent of RBCs [
         <a href="#rid29">
          29-32
         </a>
         ].
        </p>
        <p>
         Fragmentation anemia is referred to as microangiopathic hemolytic anemia (MAHA). (See
         <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">
          "Diagnosis of immune TTP", section on 'MAHA and thrombocytopenia'
         </a>
         .)
        </p>
        <p>
         The table lists common causes including  (
         <a class="graphic graphic_table graphicRef105380" href="/z/d/graphic/105380.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microangiopathies such as thrombotic thrombocytopenic purpura (TTP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic disorders with activation of intravascular clotting such as DIC
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemangiomas or intravascular devices
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical, thermal, or osmotic injury
        </p>
        <p>
        </p>
        <p>
         The cause is often apparent from the clinical setting; if not, it should be fully investigated. A rare schistocyte may be seen in a normal blood smear (due to fragmentation of a cell during sample preparation), but schistocytosis is never normal and may indicate a life-threatening condition.
        </p>
        <p class="headingAnchor" id="H2590654367">
         <span class="h3">
          Primary TMAs
         </span>
         <span class="headingEndMark">
          —
         </span>
         In thrombotic microangiopathies (TMAs), microthrombi mechanically shear RBCs, as illustrated in the scanning electron microscopy image  (
         <a class="graphic graphic_picture graphicRef81610" href="/z/d/graphic/81610.html" rel="external">
          picture 7
         </a>
         ). Thrombocytopenia is also present. (See
         <a class="medical medical_review" href="/z/d/html/1331.html" rel="external">
          "Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"
         </a>
         .)
        </p>
        <p>
         The table lists primary TMAs including  (
         <a class="graphic graphic_table graphicRef100722" href="/z/d/graphic/100722.html" rel="external">
          table 4
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TTP
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complement-mediated TMA (C-TMA)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-induced TMA (DITMA), including TMA from
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         (
         <a class="graphic graphic_table graphicRef101685" href="/z/d/graphic/101685.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shiga toxin-induced hemolytic uremic syndrome (HUS)
        </p>
        <p>
        </p>
        <p>
         Presenting features and laboratory testing, including testing for ADAMTS13 activity are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Evaluation for primary TMA syndromes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2672975148">
         <span class="h3">
          Systemic conditions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe infections or
         </strong>
         <strong>
          DIC
         </strong>
         – DIC involves activation of the coagulation cascade, usually from release or expression of tissue factor. Fibrin deposition and formation of platelet thrombi cause mechanical shearing of red cells on the fibrin strands  (
         <a class="graphic graphic_picture graphicRef81610" href="/z/d/graphic/81610.html" rel="external">
          picture 7
         </a>
         ). Causes of DIC include sepsis, trauma, malignancy, and obstetric complications  (
         <a class="graphic graphic_table graphicRef58104" href="/z/d/graphic/58104.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer
         </strong>
         – Tumor blood vessels are structurally abnormal and may cause fibrin stranding and fragmentation hemolysis similar to DIC [
         <a href="#rid33">
          33
         </a>
         ]. Some cancers cause migratory superficial thrombophlebitis or (Trousseau syndrome). The hypercoagulable state is primarily due to release of tissue factor and cancer procoagulant from tumor cells. (See
         <a class="medical medical_review" href="/z/d/html/1353.html" rel="external">
          "Cancer-associated hypercoagulable state: Causes and mechanisms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CAPS
         </strong>
         – Catastrophic antiphospholipid syndrome (CAPS) can produce microangiopathic hemolysis and a DIC-like picture. Germline variants in genes regulating complement have been found in up to 50 percent of patients [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106168.html" rel="external">
          "Catastrophic antiphospholipid syndrome (CAPS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe hypertension
         </strong>
         – Severe hypertension can cause microangiopathic hemolysis [
         <a href="#rid35">
          35
         </a>
         ]. The presumed mechanism is endothelial/vascular injury, which causes fibrin strand formation and shearing of RBCs. (See
         <a class="medical medical_review" href="/z/d/html/3833.html" rel="external">
          "Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults", section on 'Mechanisms of vascular injury'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">
          "Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study involving 97 people with severe hypertension, 27 percent had MAHA [
         <a href="#rid36">
          36
         </a>
         ]. MAHA correlated with disease severity; compared with controls, those with MAHA had higher blood pressure, higher creatinine, and greater likelihood of dialysis (58 versus 3 percent). (See
         <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">
          "Evaluation and treatment of hypertensive emergencies in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3830.html" rel="external">
          "Management of severe asymptomatic hypertension (hypertensive urgencies) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H371354927">
         <span class="h3">
          Pregnancy disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy-associated disorders that can cause MAHA are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unclear cause
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/6681.html" rel="external">
          "Thrombocytopenia in pregnancy", section on 'Determining the likely cause(s)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">
          "Anemia in pregnancy", section on 'Other anemias'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DIC
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4460.html" rel="external">
          "Disseminated intravascular coagulation (DIC) during pregnancy: Clinical findings, etiology, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130462.html" rel="external">
          "Disseminated intravascular coagulation (DIC) during pregnancy: Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preeclampsia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/126975.html" rel="external">
          "Hypertensive disorders in pregnancy: Approach to differential diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">
          "Preeclampsia: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">
          "Preeclampsia: Antepartum management and timing of delivery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6791.html" rel="external">
          "Preeclampsia with severe features: Delaying delivery in pregnancies remote from term"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HELLP syndrome
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">
          "HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1946965616">
         <span class="h3">
          Hemangiomas and other vascular lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Kasabach-Merritt phenomenon was first described as a consumptive coagulopathy with capillary hemangiomas [
         <a href="#rid37">
          37
         </a>
         ]. However, this phenomenon is more typically associated with kaposiform hemangioendotheliomas, an aggressive form of giant hemangioma [
         <a href="#rid38">
          38-40
         </a>
         ]. In approximately half of infants affected, the angiomas are noted at birth, commonly on the trunk, retroperitoneum, arms, shoulders, legs, face, and neck. The Kasabach-Merritt phenomenon causes MAHA with severe thrombocytopenia, hypofibrinogenemia, and elevated fibrin degradation products. (See
         <a class="medical medical_review" href="/z/d/html/86314.html" rel="external">
          "Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)", section on 'Kasabach-Merritt phenomenon'
         </a>
         .)
        </p>
        <p>
         Less common vascular lesions causing hemolysis include atrioventricular malformations, calcific aortic stenosis, left atrial myxoma, and cardiac metastases [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2874489971">
         <span class="h3">
          Intravascular devices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain intravascular devices can fragment RBCs by shear stress, turbulence, or direct mechanical trauma, especially with a foreign nonendothelialized surface:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodialysis
         </strong>
         – Damage to RBCs is an unavoidable side effect of extracorporeal hemodialysis. Acute hemolysis can also occur with obstructions within the extracorporeal circuit, kinking of blood tubing, excessive flow, or improper cannula or catheter dimensions [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Certain contaminants in the water can cause hemolysis. (See
         <a class="local">
          'Liver and kidney disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TIPS
         </strong>
         – Transjugular intrahepatic portosystemic shunts (TIPS) and coil embolization can cause hemolysis; one series described MAHA in approximately 10 percent of patients with a TIPS that resolved after 12 to 15 weeks [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiopulmonary bypass
         </strong>
         – Postperfusion syndrome, with fever, acute intravascular hemolysis, leukopenia, and systemic inflammation can occur following cardiopulmonary bypass. Some patients develop pulmonary dysfunction and acute respiratory distress syndrome. The mechanism is thought to involve binding and activation of complement on the RBC surface as blood passes through the oxygenator [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ventricular assist device
         </strong>
         – Severe hemolysis with a ventricular assist device implantation has been estimated at approximately 3 percent [
         <a href="#rid46">
          46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1492.html" rel="external">
          "Short-term mechanical circulatory assist devices"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ECMO
         </strong>
         – Extracorporeal membrane oxygenation (ECMO) can shear RBCs and/or activate clotting on the circuit. (See
         <a class="medical medical_review" href="/z/d/html/131002.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: The role of transesophageal echocardiography (TEE)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percutaneous thrombectomy
         </strong>
         – Certain thrombectomy devices can cause mechanical trauma to RBCs [
         <a href="#rid48">
          48,49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1565.html" rel="external">
          "Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis", section on 'Thrombolysis and thrombectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prosthetic heart valves
         </strong>
         – Hemodynamic turbulence can cause MAHA and thrombocytopenia (Waring blender syndrome)  (
         <a class="graphic graphic_picture graphicRef74544" href="/z/d/graphic/74544.html" rel="external">
          picture 8
         </a>
         ) [
         <a href="#rid50">
          50
         </a>
         ]. This is most common with leaky prosthetic valves or other foreign materials [
         <a href="#rid51">
          51,52
         </a>
         ]. Aortic valve prostheses cause more hemolysis than mitral prostheses due to their higher pressure gradient, although dysfunctional prosthetic mitral valves can also cause MANA [
         <a href="#rid53">
          53
         </a>
         ]. Valve replacement or re-repair may be indicated. (See
         <a class="medical medical_review" href="/z/d/html/8134.html" rel="external">
          "Overview of the management of patients with prosthetic heart valves", section on 'Hemolytic anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2715600682">
         <span class="h3">
          Foot strike or hand strike
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repetitive, forceful physical impact can lyse RBCs [
         <a href="#rid54">
          54-56
         </a>
         ]. The classic example is march hemoglobinuria (foot-strike hemolysis, runners hemoglobinuria) after marching, jogging, or marathon running, especially on hard surfaces with poorly cushioned shoes [
         <a href="#rid57">
          57-59
         </a>
         ]. Bongo drumming is another example. Anemia is rarely severe and can often be remedied by changing the footwear or location of running [
         <a href="#rid60">
          60
         </a>
         ]. An underlying RBC disorder may be present [
         <a href="#rid58">
          58,61-65
         </a>
         ]. If hemolysis does not resolve with interruption of the activity, evaluation for other anemias should be pursued.
        </p>
        <p class="headingAnchor" id="H439573637">
         <span class="h3">
          Thermal and osmotic injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inadvertent overheating of RBCs can cause heat denaturation. This is rare. Causes include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improperly set blood warming devices (temperatures &gt;45°C [&gt;113°F]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive thermal burns [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Heat stroke is unlikely to cause hemolysis.
        </p>
        <p>
         Abrupt changes in blood osmolality can cause lyse RBCs as free water enters or leaves the cell.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low serum osmolality with RBC hyperhydration and swelling:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RBC transfusion combined with a hypotonic solution.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Freshwater drowning.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemodialysis with inadvertent use of a very dilute dialysate [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High serum osmolality with RBC dehydration:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RBC transfusion combined with a hypertonic solution.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Saltwater drowning.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemodialysis with a very concentrated dialysate [
         <a href="#rid67">
          67,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         RBCs undergo a form of xerocytosis. (See
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Other causes of xerocytosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management requires rapid recognition and restoration of isotonicity. Hemodialysis may be helpful in severe cases.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4005991946">
         <span class="h2">
          Hypersplenism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypersplenism involves splenic sequestration of blood cells that causes one or more cytopenias. The spleen is often enlarged and congested with blood, but hypersplenism and splenomegaly do not always coexist. All normal splenic functions are accentuated, including sequestration of RBCs as well as increased clearance by splenic macrophages. (See
         <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">
          "Splenomegaly and other splenic disorders in adults", section on 'Hypersplenism'
         </a>
         .)
        </p>
        <p>
         Hypersplenism can occur with liver disease, especially cirrhosis with increased portal pressure, and portal or hepatic vein thrombosis with portal hypertension [
         <a href="#rid69">
          69
         </a>
         ]. The table lists causes  (
         <a class="graphic graphic_table graphicRef69397" href="/z/d/graphic/69397.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p>
         Additional changes with hypersplenism:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild thrombocytopenia and neutropenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spherocytes, induced by splenic macrophages, and teardrop-shaped RBCs, formed by cell membrane distortion as cells traverse the splenic cordal-sinus barrier.
        </p>
        <p>
        </p>
        <p>
         Management involves treating the underlying cause and avoiding interventions that could worsen hepatic or splenic function. For significant splenomegaly, high-impact activities may be avoided. Splenectomy is generally reserved for massive splenomegaly or severe cytopenias. Massive splenomegaly is frequently associated with expansion of the plasma volume, and the hemoglobin may underestimate the RBC mass. (See
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy", section on 'Indications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3621778733">
         <span class="h2">
          Liver and kidney disease
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alterations in the cholesterol and phospholipid content of the membrane bilayer impair membrane fluidity; the cholesterol increase is usually proportionately greater than the phospholipid increase, and fatty acid damage may occur [
         <a href="#rid69">
          69-72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Target cells  (
         <a class="graphic graphic_picture graphicRef80318" href="/z/d/graphic/80318.html" rel="external">
          picture 9
         </a>
         ), spur cells  (
         <a class="graphic graphic_picture graphicRef120809" href="/z/d/graphic/120809.html" rel="external">
          picture 10
         </a>
         ), burr cells  (
         <a class="graphic graphic_picture graphicRef121023" href="/z/d/graphic/121023.html" rel="external">
          picture 11
         </a>
         ), and stomatocytes  (
         <a class="graphic graphic_picture graphicRef75535" href="/z/d/graphic/75535.html" rel="external">
          picture 12
         </a>
         ) may occur. The figure illustrates the mechanisms  (
         <a class="graphic graphic_figure graphicRef55556" href="/z/d/graphic/55556.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7088.html" rel="external">
          "Burr cells, acanthocytes, and target cells: Disorders of red blood cell membrane", section on 'Pathophysiology (burr cells and acanthocytes)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Spur cell anemia
         </strong>
         – Spur cell anemia is associated with end-stage liver disease, with median survival measured in weeks to months. Liver transplantation can be curative. (See
         <a class="medical medical_review" href="/z/d/html/7088.html" rel="external">
          "Burr cells, acanthocytes, and target cells: Disorders of red blood cell membrane", section on 'RBC changes in liver disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Stomatocytosis
         </strong>
         – Stomatocytosis caused by liver disease or alcohol ingestion leads to trapping in the spleen and phagocytosis by reticuloendothelial macrophages. (See
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Other causes of stomatocytosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Hemolysis is usually mild. Anemia of chronic disease/anemia of inflammation, variceal bleeding, and iron deficiency may coexist. (See
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Wilson disease
         </strong>
         – Wilson disease can cause fulminant liver failure and hemolysis from copper toxicity. (See
         <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">
          "Wilson disease: Clinical manifestations, diagnosis, and natural history"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Microangiopathic
         </strong>
         – MAHA can be due to a thrombotic microangiopathy or systemic disorder such as uncontrolled hypertension. (See
         <a class="local">
          'Primary TMAs'
         </a>
         above and
         <a class="local">
          'Systemic conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Uremia
         </strong>
         – Uremia may modestly shorten RBC survival due to increased osmotic fragility [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemodialysis
         </strong>
         – A case report from the 1970s described hemolysis precipitated by chloramine in tap water [
         <a href="#rid74">
          74
         </a>
         ]. Oxidative RBC damage due to alterations in glutathione metabolism has been implicated [
         <a href="#rid75">
          75,76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1891.html" rel="external">
          "Contaminants in water used for hemodialysis", section on 'Disinfectants added to drinking water'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3106137171">
         <span class="h2">
          PNH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, clonal hemolytic anemia due to loss of complement inhibition. (See
         <a class="medical medical_review" href="/z/d/html/7156.html" rel="external">
          "Pathogenesis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p>
         Clinical findings include intravascular hemolysis and complications of circulating free heme (thrombosis, fatigue, abdominal pain, erectile dysfunction). Flow cytometry demonstrates lack of glycosylphosphatidylinositol (GPI)-anchored proteins. (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7163.html" rel="external">
          "Treatment and prognosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H185878595">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pace of the evaluation, testing sequentially or simultaneously, and need for immediate hematologist input depends on the acuity and likelihood of specific diagnoses. Most individuals can be readily treated and recover, but some conditions are potentially life-threatening and must be evaluated and treated rapidly.
        </p>
        <p>
         The following discussion presumes Coombs-negative (direct antiglobulin test [DAT]-negative) hemolysis has been established  (
         <a class="graphic graphic_algorithm graphicRef108335" href="/z/d/graphic/108335.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3292913649">
         <span class="h2">
          Assess disease severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Major red flags for potentially life-threatening hemolytic anemia include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection requiring systemic antibiotics, especially systemic clostridial infection. (See
         <a class="local">
          'Infections (RBC parasites and intracellular bacteria)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemodynamic instability and need for transfusion (hemoglobin rapidly declining or &lt;7 to 8 g/dL). (See
         <a class="local">
          'Transfusion for severe anemia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant intravascular hemolysis or a disseminated intravascular hemolysis (DIC)-like picture. (See
         <a class="local">
          'Kidney protection in intravascular hemolysis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1157345180">
         <span class="h2">
          Determine the cause
         </span>
        </p>
        <p class="headingAnchor" id="H3504224418">
         <span class="h3">
          Important clues from the clinical history
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of anemia or heritable disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New exposures to drugs, including over-the-counter remedies and supplements
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exposure to foods containing fava beans
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent transfusions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever or other systemic symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyspnea or lightheadedness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of thrombosis (leg swelling, dyspnea, neurologic symptoms)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2657176606">
         <span class="h3">
          Review laboratory findings
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confirm hemolysis
         </strong>
         – The table summarizes laboratory findings  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anemia
         </strong>
         – May be mild or absent if hemolysis is mild or reticulocytosis is robust.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reticulocyte count
         </strong>
         – Increased, unless bone marrow function is impaired.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lactate dehydrogenase (LDH)
         </strong>
         – Increased but nonspecific; LDH can be elevated from kidney or liver disease, muscle injury, cancer (especially lymphoma), and pancreatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bilirubin
         </strong>
         – Increased, mostly indirect.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Haptoglobin
         </strong>
         – Decreased or undetectable. Haptoglobin may be increased in severe inflammatory states and may be decreased in liver disease and with large hematomas. (See
         <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">
          "Acute phase reactants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Artifact
         </strong>
         – If the clinical picture and laboratory findings are discordant, repeat the complete blood count (CBC) to verify that hemolysis is present rather than artifactual.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hemolysis can occur during phlebotomy due to [
         <a href="#rid77">
          77,78
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blood drawn rapidly through a small-gauge needle
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Traumatic or difficult blood draw
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prolonged tourniquet time
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sampling site other than the antecubital fossa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Forcibly squirting the blood from a syringe into an evacuated tube
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Damage during delivery of the blood sample to the laboratory
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A systematic review of 16 studies concluded that the strongest predictor of hemolysis in blood obtained in the emergency department was drawing blood through an existing intravenous catheter; use of a butterfly needle for phlebotomy was the most effective means of avoiding in vitro hemolysis [
         <a href="#rid79">
          79-81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Narrow the diagnosis
         </strong>
         – Once hemolysis has been documented based on the CBC, reticulocyte count, and blood smear, the next step is to determine the cause. Obvious causes may be apparent on the blood smear; if not, the appropriate next step is often to obtain a Coombs test (DAT) as illustrated in the flow chart  (
         <a class="graphic graphic_algorithm graphicRef108335" href="/z/d/graphic/108335.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Immune hemolysis is typically Coombs-positive; non-immune hemolysis is Coombs-negative. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Cause not obvious - start with Coombs test'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CBC
         </strong>
         – Isolated anemia is seen in heritable/genetic red blood cell (RBC) abnormalities; drug-induced hemolysis; and mechanical, thermal, or osmotic RBC lysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Leukopenia, leukocytosis, and thrombocytopenia are seen in certain infections, primary thrombotic microangiopathies (TMAs), systemic and pregnancy-related conditions, hypersplenism, and liver disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          RBC morphology
         </strong>
         – The laboratory may report findings that suggest the cause:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Spherocytes
         </strong>
         – Hereditary spherocytosis, drug-induced hemolysis, hypersplenism
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Schistocytes
         </strong>
         – TMA, systemic or vascular condition with RBC fragmentation
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stomatocytes
         </strong>
         – Hereditary stomatocytosis, liver disease, certain drugs
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          RBC ghosts
         </strong>
         –
         <em>
          Clostridium perfringens
         </em>
         sepsis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Bite cells
         </strong>
         – Glucose-6-phosphate dehydrogenase (G6PD) deficiency, oxidant hemolysis
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Intracellular parasites
         </strong>
         – Malaria, babesiosis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney function
         </strong>
         – Kidney dysfunction can accompany Shiga toxin-mediated hemolytic uremic syndrome (ST-HUS) or complement-mediated (C-TMA). (See
         <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">
          "Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver function
         </strong>
         – Liver dysfunction can induce membrane abnormalities and hypersplenism. (See
         <a class="local">
          'Liver and kidney disease'
         </a>
         above and
         <a class="local">
          'Hypersplenism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Coagulation studies
         </strong>
         – Liver disease and disseminated intravascular coagulation (DIC) prolong the prothrombin time (PT) and activated partial thromboplastin time (aPTT) and reduce the fibrinogen.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pink/red serum and urine
         </strong>
         – The serum and urine should be clear yellow. Intravascular hemolysis liberates free heme, making the serum and urine amber to red. Urinalysis is positive for heme and negative for RBCs. Free heme in serum is confirmatory; appropriate treatments should not be delayed while obtaining this testing. (See
         <a class="local">
          'Kidney protection in intravascular hemolysis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3508770784">
         <span class="h3">
          Additional testing to determine the cause
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected infection
         </strong>
         – Cultures. (See
         <a class="medical medical_review" href="/z/d/html/7672.html" rel="external">
          "Clostridial myonecrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">
          "Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5670.html" rel="external">
          "Babesiosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected oxidant hemolysis
         </strong>
         – G6PD testing. (See
         <a class="medical medical_review" href="/z/d/html/7109.html" rel="external">
          "Genetics and pathophysiology of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected DIC or TMA
         </strong>
         – Coagulation studies, ADAMTS13 activity. (See
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected hypersplenism
         </strong>
         – Splenic imaging. (See
         <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">
          "Splenomegaly and other splenic disorders in adults", section on 'Hypersplenism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected paroxysmal nocturnal hemoglobinuria
         </strong>
         <strong>
          (PNH)
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2929444953">
         <span class="h2">
          When to consult hematology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematology input should be sought with unexplained hemolysis to guide further diagnostic testing and assist with any emergency interventions that may include plasma exchange.
        </p>
        <p class="headingAnchor" id="H2356138587">
         <span class="h1">
          GENERAL MANAGEMENT PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy depends on the cause. (See
         <a class="local">
          'Causes'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2586559707">
         <span class="h2">
          Transfusion for severe anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfusion may be indicated if there is severe anemia with hemodynamic compromise, cardiac ischemia, or hemoglobin &lt;7 to 8 g/dL. Transfusions should not be withheld if needed while awaiting diagnostic testing results, although it can be helpful to obtain a sample prior to transfusion. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3473538347">
         <span class="h2">
          Kidney protection in intravascular hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Free heme can cause acute kidney injury (AKI) and a disseminated intravascular hemolysis (DIC)-like picture. (See
         <a class="medical medical_review" href="/z/d/html/14034.html" rel="external">
          "Clinical features and diagnosis of heme pigment-induced acute kidney injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95132.html" rel="external">
          "Approach to the patient with a suspected acute transfusion reaction", section on 'Suspected acute hemolytic reaction'
         </a>
         .)
        </p>
        <p>
         Hydration is paramount to reduce the risk of AKI. (See
         <a class="medical medical_review" href="/z/d/html/14034.html" rel="external">
          "Clinical features and diagnosis of heme pigment-induced acute kidney injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H853070955">
         <span class="h2">
          Folic acid for chronic hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased RBC production requires folates. Individuals with chronic hemolysis are generally treated with daily folate (typical dose, 1 mg orally per day) unless this would create an undue burden.
        </p>
        <p class="headingAnchor" id="H2398623864">
         <span class="h2">
          Low threshold for evaluating DVT/PE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many hemolytic anemias, especially with severe or intravascular hemolysis, increase the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). (See
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p>
         Routine surveillance is generally not used outside of a clinical trial, but the threshold for evaluation should be low and individuals with hemolysis should seek medical attention for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leg swelling
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained dyspnea, cough, or pleuritic chest pain
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3457125789">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">
          "Society guideline links: Anemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6282809">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Non-immune hemolysis includes non-antibody-mediated processes that cause anemia, increased reticulocyte count, high lactate dehydrogenase (LDH) and indirect bilirubin, and low haptoglobin  (
         <a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">
          table 1
         </a>
         ), along with a negative direct antiglobulin (Coombs) test (DAT). (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic alterations of red blood cell (RBC) membrane proteins, enzymes, or hemoglobin  (
         <a class="graphic graphic_figure graphicRef117376" href="/z/d/graphic/117376.html" rel="external">
          figure 1
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infectious organisms that invade and lyse RBCs
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mechanical, thermal, and osmotic injury
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oxidant drugs and toxins  (
         <a class="graphic graphic_table graphicRef74254" href="/z/d/graphic/74254.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RBC fragmentation from a thrombotic microangiopathy  (
         <a class="graphic graphic_table graphicRef105380" href="/z/d/graphic/105380.html" rel="external">
          table 3
         </a>
         ) or a systemic disorder  (
         <a class="graphic graphic_table graphicRef58104" href="/z/d/graphic/58104.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypersplenism  (
         <a class="graphic graphic_table graphicRef69397" href="/z/d/graphic/69397.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Liver or kidney disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Mechanisms and typical findings are discussed above. (See
         <a class="local">
          'Causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Disease severity determines the pace of the evaluation and need for immediate interventions. An initial evaluation identifies Coombs (DAT)-negative hemolysis  (
         <a class="graphic graphic_algorithm graphicRef108335" href="/z/d/graphic/108335.html" rel="external">
          algorithm 1
         </a>
         ). Clues from the history and initial laboratory testing narrow the diagnostic possibilities. Hematology consultation should be obtained if there is diagnostic uncertainty and/or need for rapid interventions. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Management depends on the cause. General principles include transfusion for severe anemia with hemodynamic compromise or cardiac ischemia, hydration for significant intravascular hemolysis,
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         for chronic hemolysis, and a low threshold for evaluating thromboembolic complications. (See
         <a class="local">
          'General management principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1034235919">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
        </p>
        <p>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Egan ES, Jiang RH, Moechtar MA, et al. Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion. Science 2015; 348:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams JH, Sim BK, Dolan SA, et al. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 1992; 89:7085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994; 180:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 1994; 264:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadelman RB, Horowitz HW, Hsieh TC, et al. Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. N Engl J Med 1997; 337:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falagas ME, Klempner MS. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Clin Infect Dis 1996; 22:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorenflot A, Moubri K, Precigout E, et al. Human babesiosis. Ann Trop Med Parasitol 1998; 92:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beattie JF, Michelson ML, Holman PJ. Acute babesiosis caused by Babesia divergens in a resident of Kentucky. N Engl J Med 2002; 347:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stowell CP, Gelfand JA, Shepard JA, Kratz A. Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea. N Engl J Med 2007; 356:2313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun T, Tenenbaum MJ, Greenspan J, et al. Morphologic and clinical observations in human infection with Babesia microti. J Infect Dis 1983; 148:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kager PA, Rees PH. Haematological investigations in visceral leishmaniasis. Trop Geogr Med 1986; 38:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biswas T, Ghosh DK, Mukherjee N, Ghosal J. Lipid peroxidation of erythrocytes in visceral leishmaniasis. J Parasitol 1997; 83:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biswas T, Pal JK, Naskar K, et al. Lipid peroxidation of erythrocytes during anemia of the hamsters infected with Leishmania donovani. Mol Cell Biochem 1995; 146:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hübl W, Mostbeck B, Hartleb H, et al. Investigation of the pathogenesis of massive hemolysis in a case of Clostridium perfringens septicemia. Ann Hematol 1993; 67:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly JJ, Haeusler MN, Hogan CJ, Wood EM. Massive intravascular haemolysis with T-activation and disseminated intravascular coagulation due to clostridial sepsis. Br J Haematol 2006; 134:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIlwaine K, Leach MT. Clostridium perfringens septicaemia. Br J Haematol 2013; 163:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett JM, Healey PJ. Spherocytic hemolytic anemia and acute cholecystitis caused by Clostridium welchii. N Engl J Med 1963; 268:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard JA, Whalley PJ. Abortion complicated by Clostridium perfringens infection. Am J Obstet Gynecol 1971; 111:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean HM, Decker CL, Baker LD. Temporary survival in clostridial hemolysis with absence of circulating red cells. N Engl J Med 1967; 277:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez FJ, Ritter MJ, Tauscher CD, Moore SB. Transfusion medicine illustrated. Massive hemolysis secondary to alpha-toxin release. Transfusion 2005; 45:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McArthur HL, Dalal BI, Kollmannsberger C. Intravascular hemolysis as a complication of clostridium perfringens sepsis. J Clin Oncol 2006; 24:2387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meinders AJ, Dijkstra I. Massive hemolysis and erythrophagocytosis in severe sepsis. Blood 2014; 124:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Virgilio C, Klein S, Chang L, et al. Clostridial bacteremia: implications for the surgeon. Am Surg 1991; 57:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kojima H, Shimizu Y, Sugiyama K. Clostridium perfringens bacteremia and intravascular hemolysis. QJM 2023; 116:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogstad B, Ritland S, Lunde S, Hagen AG. Clostridium perfringens septicemia with massive hemolysis. Infection 1993; 21:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai IK, Yen MY, Ho IC, et al. Clostridium perfringens septicemia with massive hemolysis. Scand J Infect Dis 1989; 21:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherer DC, DeBuron-Connors I, Minnick MF. Characterization of Bartonella bacilliformis flagella and effect of antiflagellin antibodies on invasion of human erythrocytes. Infect Immun 1993; 61:4962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zini G, d'Onofrio G, Briggs C, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol 2012; 34:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saigo K, Jiang M, Tanaka C, et al. Usefulness of automatic detection of fragmented red cells using a hematology analyzer for diagnosis of thrombotic microangiopathy. Clin Lab Haematol 2002; 24:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesesve JF, Salignac S, Lecompte T, Bordigoni P. Automated measurement of schistocytes after bone marrow transplantation. Bone Marrow Transplant 2004; 34:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesesve JF, Salignac S, Alla F, et al. Comparative evaluation of schistocyte counting by an automated method and by microscopic determination. Am J Clin Pathol 2004; 121:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YR, van't Oever R, Landayan M, Bearden J. Automated red blood cell differential analysis on a multi-angle light scatter/fluorescence hematology analyzer. Cytometry B Clin Cytom 2003; 56:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaturvedi S, Braunstein EM, Yuan X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavras H, Brown WC, Brown JJ, et al. Microangipathic hemolytic anemia and the development of the malignant phase of hypertension. Circ Res 1971; 28:Suppl 2:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005; 45:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasabach H, Merritt K. Capillary hemangioma with extensive purpura. Am J Dis Child 1940; 59:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blei F. New clinical observations in hemangiomas. Semin Cutan Med Surg 1999; 18:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 1997; 130:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman AD, Hoffman A, Volterra F, et al. Intracaval and intracardiac metastatic nonseminomatous germ cell tumor: a rare cause of hemolytic anemia and thrombocytopenia. Cancer Invest 2002; 20:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polaschegg HD. Red blood cell damage from extracorporeal circulation in hemodialysis. Semin Dial 2009; 22:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanyal AJ, Freedman AM, Purdum PP, et al. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shim D, Wechsler DS, Lloyd TR, Beekman RH 3rd. Hemolysis following coil embolization of a patent ductus arteriosus. Cathet Cardiovasc Diagn 1996; 39:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salama A, Hugo F, Heinrich D, et al. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 1988; 318:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genovese EA, Dew MA, Teuteberg JJ, et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg 2009; 88:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kummerfeldt CE, Toma A, Badheka AO, et al. Severe hemolytic anemia and acute kidney injury after percutaneous continuous-flow ventricular assistance. Circ Heart Fail 2011; 4:e20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mair DC, Eastlund T, Rosen G, et al. Hemolysis during percutaneous mechanical thrombectomy can mimic a hemolytic transfusion reaction. Transfusion 2005; 45:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner HJ, Müller-Hülsbeck S, Pitton MB, et al. Rapid thrombectomy with a hydrodynamic catheter: results from a prospective, multicenter trial. Radiology 1997; 205:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismeno G, Renzulli A, Carozza A, et al. Intravascular hemolysis after mitral and aortic valve replacement with different types of mechanical prostheses. Int J Cardiol 1999; 69:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia MJ, Vandervoort P, Stewart WJ, et al. Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation. J Am Coll Cardiol 1996; 27:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo TC, Freeman WK, Schaff HV, Orszulak TA. Mechanisms of hemolysis after mitral valve repair: assessment by serial echocardiography. J Am Coll Cardiol 1998; 32:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam BK, Cosgrove DM, Bhudia SK, Gillinov AM. Hemolysis after mitral valve repair: mechanisms and treatment. Ann Thorac Surg 2004; 77:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan J, Kiernan W, Merker HJ, et al. Red cell membrane skeletal changes in marathon runners. Int J Sports Med 1998; 19:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Telford RD, Sly GJ, Hahn AG, et al. Footstrike is the major cause of hemolysis during running. J Appl Physiol (1985) 2003; 94:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller BJ, Pate RR, Burgess W. Foot impact force and intravascular hemolysis during distance running. Int J Sports Med 1988; 9:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abarbanel J, Benet AE, Lask D, Kimche D. Sports hematuria. J Urol 1990; 143:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deitrick RW. Intravascular haemolysis in the recreational runner. Br J Sports Med 1991; 25:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dang CV. Runner's anemia. JAMA 2001; 286:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagov SE. March hemoglobinuria treated with rubber insoles: two case reports. J Am Coll Health Assoc 1970; 19:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blum SF, Sullivan JM, Gardner FH. The exacerbation of hemolysis in paroxysmal nocturnal hemoglobinuria by strenuous exercise. Blood 1967; 30:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banga JP, Pinder JC, Gratzer WB, et al. An erythrocyte membrane-protein anomaly in march haemoglobinuria. Lancet 1979; 2:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard JF, Galand C, Boivin P. [March hemoglobinuria. One case with erythrocyte glutathione peroxidase deficiency]. Nouv Presse Med 1975; 4:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt OS, Lux SE, Nathan DG. Exercise-induced hemolysis in xerocytosis. Erythrocyte dehydration and shear sensitivity. J Clin Invest 1981; 68:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt OS. Exercise-induced hemolysis in sickle cell anemia: shear sensitivity and erythrocyte dehydration. Blood 1982; 59:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence C, Atac B. Hematologic changes in massive burn injury. Crit Care Med 1992; 20:1284.
          </a>
         </li>
         <li class="breakAll">
          Bregman H, Daugirdas JT, Ing TS. Complications during hemodialysis. In: Handbook of Dialysis, Daugirdas JT, Ing TS (Eds), Little Brown, New York 1994. p.149.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulligan I, Parfrey P, Phillips ME, et al. Acute haemolysis due to concentrated dialysis fluid. Br Med J (Clin Res Ed) 1982; 284:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper RA. Hemolytic syndromes and red cell membrane abnormalities in liver disease. Semin Hematol 1980; 17:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper RA, Kimball DB, Durocher JR. Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease. N Engl J Med 1974; 290:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen DW, Manning N. Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl-CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase. A model of spur cell anemia. Blood 1996; 87:3489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen DW, Manning N. Abnormal phospholipid metabolism in spur cell anemia: decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anemia erythrocytes. Blood 1994; 84:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu SG, Jeng FR, Wei SY, et al. Red blood cell osmotic fragility in chronically hemodialyzed patients. Nephron 1998; 78:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yawata Y, Howe R, Jacob HS. Abnormal red cell metabolism causing hemolysis in uremia. A defect potentiated by tap water hemodialysis. Ann Intern Med 1973; 79:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paşaoğlu H, Muhtaroğlu S, Güneş M, Utaş C. The role of the oxidative state of glutathione and glutathione-related enzymes in anemia of hemodialysis patients. Clin Biochem 1996; 29:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usberti M, Lima G, Arisi M, et al. Effect of exogenous reduced glutathione on the survival of red blood cells in hemodialyzed patients. J Nephrol 1997; 10:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns ER, Yoshikawa N. Hemolysis in serum samples drawn by emergency department personnel versus laboratory phlebotomists. Lab Med 2002; 33:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baer DM, Ernst DJ, Willeford SI, Gambino R. Investigating elevated potassium values. MLO Med Lab Obs 2006; 38:24, 26, 30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wollowitz A, Bijur PE, Esses D, John Gallagher E. Use of butterfly needles to draw blood is independently associated with marked reduction in hemolysis compared to intravenous catheter. Acad Emerg Med 2013; 20:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong ME, Chan YH, Lim CS. Reducing blood sample hemolysis at a tertiary hospital emergency department. Am J Med 2009; 122:1054.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyer NJ, Derzon JH, Winges L, et al. Effectiveness of practices to reduce blood sample hemolysis in EDs: a laboratory medicine best practices systematic review and meta-analysis. Clin Biochem 2012; 45:1012.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7168 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25954012" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1496004" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A family of erythrocyte binding proteins of malaria parasites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8046329" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8009226" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9203428" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8722936" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9683900" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Human babesiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12200568" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Acute babesiosis caused by Babesia divergens in a resident of Kentucky.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17538091" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6684141" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Morphologic and clinical observations in human infection with Babesia microti.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3810841" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Haematological investigations in visceral leishmaniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9057713" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Lipid peroxidation of erythrocytes in visceral leishmaniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7565650" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Lipid peroxidation of erythrocytes during anemia of the hamsters infected with Leishmania donovani.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8373904" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Investigation of the pathogenesis of massive hemolysis in a case of Clostridium perfringens septicemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16822287" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Massive intravascular haemolysis with T-activation and disseminated intravascular coagulation due to clostridial sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24016137" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clostridium perfringens septicaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Spherocytic hemolytic anemia and acute cholecystitis caused by Clostridium welchii
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4328673" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Abortion complicated by Clostridium perfringens infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4292336" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Temporary survival in clostridial hemolysis with absence of circulating red cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15660817" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Transfusion medicine illustrated. Massive hemolysis secondary to alpha-toxin release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710038" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Intravascular hemolysis as a complication of clostridium perfringens sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25247212" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Massive hemolysis and erythrophagocytosis in severe sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2048853" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clostridial bacteremia: implications for the surgeon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36222591" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clostridium perfringens bacteremia and intravascular hemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8449584" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clostridium perfringens septicemia with massive hemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2555910" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clostridium perfringens septicemia with massive hemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8225570" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Characterization of Bartonella bacilliformis flagella and effect of antiflagellin antibodies on invasion of human erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22081912" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12452815" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Usefulness of automatic detection of fragmented red cells using a hematology analyzer for diagnosis of thrombotic microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15220961" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Automated measurement of schistocytes after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15151214" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Comparative evaluation of schistocyte counting by an automated method and by microscopic determination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14582136" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Automated red blood cell differential analysis on a multi-angle light scatter/fluorescence hematology analyzer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4748253" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31812994" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5568228" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Microangipathic hemolytic anemia and the development of the malignant phase of hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596574" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Microangiopathic hemolysis and renal failure in malignant hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Capillary hemangioma with extensive purpura
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468038" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : New clinical observations in hemangiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9108863" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9385948" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12449733" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Intracaval and intracardiac metastatic nonseminomatous germ cell tumor: a rare cause of hemolytic anemia and thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19558629" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Red blood cell damage from extracorporeal circulation in hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8550045" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The hematologic consequences of transjugular intrahepatic portosystemic shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8933975" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Hemolysis following coil embolization of a patent ductus arteriosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3340119" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19766801" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22086832" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Severe hemolytic anemia and acute kidney injury after percutaneous continuous-flow ventricular assistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16078914" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Hemolysis during percutaneous mechanical thrombectomy can mimic a hemolytic transfusion reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9393520" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Rapid thrombectomy with a hydrodynamic catheter: results from a prospective, multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10549841" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intravascular hemolysis after mitral and aortic valve replacement with different types of mechanical prostheses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8557912" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741517" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Mechanisms of hemolysis after mitral valve repair: assessment by serial echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726060" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hemolysis after mitral valve repair: mechanisms and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9506794" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Red cell membrane skeletal changes in marathon runners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12391035" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Footstrike is the major cause of hemolysis during running.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3366521" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Foot impact force and intravascular hemolysis during distance running.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2184253" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sports hematuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1810610" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Intravascular haemolysis in the recreational runner.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11495622" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Runner's anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5496361" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : March hemoglobinuria treated with rubber insoles: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6054666" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The exacerbation of hemolysis in paroxysmal nocturnal hemoglobinuria by strenuous exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/91785" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : An erythrocyte membrane-protein anomaly in march haemoglobinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1134932" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : [March hemoglobinuria. One case with erythrocyte glutathione peroxidase deficiency].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7276163" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Exercise-induced hemolysis in xerocytosis. Erythrocyte dehydration and shear sensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7074213" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Exercise-induced hemolysis in sickle cell anemia: shear sensitivity and erythrocyte dehydration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1521443" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Hematologic changes in massive burn injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1521443" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hematologic changes in massive burn injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6803872" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Acute haemolysis due to concentrated dialysis fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6990496" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Hemolytic syndromes and red cell membrane abnormalities in liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4363887" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8605368" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl-CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase. A model of spur cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8049442" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Abnormal phospholipid metabolism in spur cell anemia: decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anemia erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9453400" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Red blood cell osmotic fragility in chronically hemodialyzed patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4748252" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Abnormal red cell metabolism causing hemolysis in uremia. A defect potentiated by tap water hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8939405" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The role of the oxidative state of glutathione and glutathione-related enzymes in anemia of hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9364318" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of exogenous reduced glutathione on the survival of red blood cells in hemodialyzed patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hemolysis in serum samples drawn by emergency department personnel versus laboratory phlebotomists
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17225675" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Investigating elevated potassium values.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24238318" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Use of butterfly needles to draw blood is independently associated with marked reduction in hemolysis compared to intravenous catheter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19854334" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Reducing blood sample hemolysis at a tertiary hospital emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22968086" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effectiveness of practices to reduce blood sample hemolysis in EDs: a laboratory medicine best practices systematic review and meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
